



KyungMann Kim, PhD, Professor and Director of the Clinical Trials Program, Department of Biostatistics and Medical Informatics (BMI) within the UW School of Medicine and Public Health, was recently awarded a 5-year U24 Cooperative Agreement from the National Cancer Institute. Dr. Kim will serve as MPI of the Coordinating Center for the HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (CASCADE Network Coordinating Center, CNCC). Suzanne Siminski, MS, MBA, CEO of the Frontier Science & Technology Research Foundation, Inc. (<https://www.frontierscience.org>), is contact PI. The 5-yr budget for the award (1U24CA275417-01) is \$7.1 M, including \$2.1 M restricted funds (pass through).

The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (<https://prevention.cancer.gov/major-programs/hiv-cervical-cancer-prevention-cascade-clinical-trials-network>) was created by the Division of Cancer Prevention of the National Cancer Institute to improve screening and preventive therapy outcomes for cervical cancer among women living with HIV. This will be accomplished by conducting pragmatic phase 3 and 4 clinical trials with 'hybrid' effectiveness-implementation designs to evaluate the effectiveness of clinically-proven interventions in intended-use setting, with a goal to optimize the cervical cancer screening, management, and pre-cancer treatment cascade for women living with HIV. The CASCADE Network will have a major focus on resource constrained settings in low- and middle-income countries (LMICs), but will also include studies addressing health disparities within the US, all with a goal to generate evidence to refine clinical practice guidelines and improve implementation of cervical cancer prevention and control programs. The CASCADE Network will consist of three UG1-funded Research Bases and up to eight UG1-funded Clinical Sites (three sites are currently funded) in addition to the U24-funded Coordinating Center. The CASCADE Blog has more information: <https://prevention.cancer.gov/news-and-events/blog/launching-cascade-clinical>

The CASCADE Network Coordinating Center (CNCC) consists of three units: Network Coordination and Scientific Review, Data Management and Reporting, and Clinical Trials Auditing. It will support the Research Bases and Clinical Sites in conducting six to eight multicenter clinical trials in LMICs over the five-year period with the following specific responsibilities:

- a) network coordination and scientific review,
- b) data management and reporting, and
- c) clinical trials auditing.

In addition, it will provide expertise in clinical trials methodology and biostatistics for CASCADE clinical trials. The Data Coordinating Center at BMI will house the CNCC Network Coordination and Scientific Review Unit and will be responsible for 1) network coordination and scientific review for the 'CASCADE' Network and 2) providing expertise in clinical trials methodology and biostatistics.

Dr. Kim is currently PI of the U24-funded (5U24CA242637) Cancer Prevention Clinical Trials Network (CP-CTNet) Data Management, Auditing, and Coordinating Center (DMACC) (<https://www.cp-ctnet-dmacc.org/public/>) with a subcontract with the Frontier Science & Technology Research Foundation, Inc. The CP-CTNet (<https://prevention.cancer.gov/major-programs/cancer-prevention-clinical-trials-network>) conducts early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis.